Predicted protein targets (top 2)
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Hydrochloric Acid SCHEMBL9469525 | 0.98 | LSS (0.56) | LSSCHRNA7 | |
| SCHEMBL1542601 | 0.95 | LSS (0.53) | LSSCHRNA7 | |
| SCHEMBL5416184 | 0.95 | LSS (0.53) | LSSCHRNA7 | |
| SCHEMBL1542294 | 0.95 | LSS (0.53) | LSSCHRNA7 | |
| SCHEMBL5710492 | 0.91 | LSS (0.50) | LSSCHRNA7 | |
| SCHEMBL5390772 | 0.86 | LSS (0.60) | LSSCHRNA7 | |
| SCHEMBL3215158 | 0.83 | LSS (0.78) | LSSCHRNA7 | |
| SCHEMBL1849257 | 0.83 | LSS (0.57) | LSSCHRNA7 | |
| SCHEMBL1018942 | 0.83 | LSS (0.57) | LSSCHRNA7 | |
| SCHEMBL1542743 | 0.83 | LSS (0.57) | LSSCHRNA7 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2023138362-A1 | WEE1 INHIBITOR, PREPARATION THEREFOR, AND USE THEREOF | 江苏天士力帝益药业有限公司 | 2023-07-27 | — | — | WO | disclosed |
| US-7241773-B2 | 3-quinuclidinyl heteroatom bridged biaryl derivatives | ABBOTT LABORATORIES (US) | 2007-07-10 | — | — | US | disclosed |
| US-20050137226-A1 | 3-Quinuclidinyl heteroatom bridged biaryl derivatives | ABBOTT LABORATORIES | 2005-06-23 | — | — | US | disclosed |
| US-20050137398-A1 | 3-Quinuclidinyl heteroatom bridged biaryl derivatives | ABBOTT LABORATORIES | 2005-06-23 | — | — | US | disclosed |
| US-5258392-A | 3-quinuclidine derivatives | AKZO N.V. (NL) | 1993-11-02 | — | — | US | disclosed |
| EP-0497415-A1 | 3-Quinuclidine derivatives | Akzo Nobel N.V. (NL) | 1992-08-05 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050137398-A1 | 3-Quinuclidinyl heteroatom bridged biaryl derivatives | CHRNA1, CHRNA2, CHRM2 | LSS 2314/4885CHRNA7 8/4885 |
| US-20050137226-A1 | 3-Quinuclidinyl heteroatom bridged biaryl derivatives | CHRNA3, CHRNA1, CHRM3 | LSS 1730/4885CHRNA7 11/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.